Associate Professor Evan Ingley BSc(Hons), PhD

Evan IngleyLaboratory Head, Cell Signalling
T:  +61 8 6151 0738

Associate Professor Evan Ingley heads the Cell Signalling group, which has an interest in understanding the signalling networks or "information highways" of both normal and diseased cells.  Evan's Honours degree at the University of Canterbury (New Zealand) included a research project on the hormonal control of genes important for cockroach reproduction, but developed an interest in understanding molecular interactions involved in cancer/leukaemia. Evan completed his PhD at The Australian National University in the John Curtin School of Medical Research (Canberra) under the direction of Professor Ian Young, working on the interaction between the cytokine Interleukin-5 (IL-5) and its receptor. For his postdoctoral studies he move to Switzerland working with Dr Brian Hemmings at the Friedrich Miescher Institute, the flagship research institute of the pharmaceutical company Novartis. Dr Hemmings had recently identified the new oncogene Akt/PKB and Evan worked on its regulation through protein-protein as well as protein-lipid interactions. On returning to Australia Evan began working in the Laboratory for Cancer Medicine at WAIMR bringing his expertise on protein-protein interactions involved in signal transduction to the labs interest in red blood cell development and lineage determination. After the labs discovery of the importance of Lyn in erythropoiesis he began establishing a focus on the signalling pathways of this molecule and set up the Cell Signalling Group.

Research overview
Currently his research group is analysing the biological and signalling consequences of mice expressing different mutations of Lyn, how the Lyn substrate Csk binding protein (Cbp) can be used to disrupt Lyn signals in cancer and leukaemia cells, and detailing two novel Lyn signalling pathways mediated by AFAP1L1 and AnkRD54, which regulate cell shape/migration/attachment/metastasis and nuclear/cytoplasmic shuttling, respectively.

A/Professor Ingley is the 'Sock it to Sarcoma! Senior Research Fellow' and his research is significantly supported by Sock it to Sarcoma!

Research projects

  • The role of the tyrosine kinase Lyn in erythropoiesis and red blood cell leukaemias.
  • Delineating novel signalling pathways intersected by Lyn.
  • Analysing Lyn pathways involved in leukaemia and cancer.
  • Structure/function analysis of Lyn signalling complexes.
  • Techniques: Yeast two-hybrid, molecular biology, cell biology, protein complexes, protein expression, protein posttranslational modifications, flow cytometry.

Selected publications

  1. Maira S-M, Galetic I, Brazil DP, Kaech S, Ingley E, Thelen M, Hemmings BA. 2001. Carboxyl-terminal modulator protein (CTMP), a negative regulator of PKB/Akt and v-Akt at the plasma membrane. Science 294:374-80. [NCBI PubMed Entry]

  2. Ingley E, McCarthy DJ, Pore, JR, Sarna MK, Adenan AS, Wright MJ, Erber W, Tilbrook PA, Klinken SP. 2005. Lyn deficiency reduces GATA-1, EKLF and STAT5, and induces extramedullary stress erythropoiesis. Oncogene 24:336-43. [NCBI PubMed Entry]

  3. Ingley E, Schneider JR, McCarthy DJ, Harder KW, Hibbs ML, Klinken SP. 2006. Csk-binding protein mediates sequential enzymatic down-regulation and degradation of Lyn in erythropoietin-stimulated cells. Journal of Biological Chemistry 281:31920-9. [NCBI PubMed Entry]

  4. Frech M, Andjelkovic M, Ingley E, Reddy KK, Falck JR, Hemmings BA. 1997. High affinity binding of inositol phosphates and phospholipids to the pleckstrin homology domain of RAC / protein kinase B and their influence on kinase activity. Journal of Biological Chemistry 272:8474-81. [NCBI PubMed Entry]

  5. Tilbrook PA, Ingley E, Williams JH, Hibbs ML, Klinken SP. 1997. Lyn tyrosine kinase is essential for erythropoietin-induced differentiation of J2E erythroid cells. EMBO Journal 16:1610-9. [NCBI PubMed Entry]

  6. Williams NK, Lucet IS, Klinken SP, Ingley E, Rossjohn J. 2009. Crystal structures of the Lyn protein tyrosine kinase domain in its Apo- and inhibitor-bound state. Journal of Biological Chemistry 284:284-291.[NCBI PubMed Entry]

  7. Ingley E, Young IG. 1991. Characterization of a Receptor for Interleukin 5 on Human Eosinophils and the Myeloid Leukaemia Line HL-60. Blood 78:339-44.[NCBI PubMed Entry]

  8. Kendrick TS, Payne CJ, Epis MR, Schneider JR, Leedman PJ, Klinken SP. Ingley E. 2008. Erythroid defects in TR-/- mice. Blood 111:3245-3248.[NCBI PubMed Entry]

  9. Samuels AS, Klinken SP, Ingley E. 2008. Liar, a novel Lyn-binding nuclear/cytoplasmic shuttling protein that influences erythropoietin-induced differentiation. Blood 113:3845-56. [NCBI PubMed Entry]

  10. Slavova-Azmanova NS, Kucera N, Satiaputra J, Stone L, Magno M, Maxwell MJ, Quilici C, Erber W, Klinken SP, Hibbs ML, Ingley E. 2013. Gain-of-function Lyn induces anemia – appropriate Lyn activity is essential for normal erythropoiesis and Epo-receptor signaling. Blood 122:262-271.[NCBI PubMed Entry]

Back To Top